Glitisol (Glibenclamide)

Glitisol (glibenclamide) is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

• Used as monotherapy in patients with newly diagnosed type 2 diabetes.
• Added to metformin or other oral antidiabetic agents when additional glucose lowering is needed.
• May be prescribed in combination with lifestyle modifications to improve overall glycemic control.
• Considered for patients who have adequate pancreatic beta‑cell function.
• Utilized in clinical practice as a cost‑effective oral hypoglycemic option.

The safety profile of Glitisol reflects the pharmacology of sulfonylureas; side effects range from mild and frequent to rare but serious.

Common

• Mild hypoglycemia, especially if meals are missed or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient visual disturbances.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including skin rash, pruritus, or angio‑edema.
• Hepatic dysfunction manifested by jaundice or elevated liver enzymes.
• Blood dyscrasias such as leukopenia or thrombocytopenia.
• Any reaction requiring emergency medical attention.

When prescribing Glitisol, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk of adverse outcomes.

• Assess renal and hepatic function before initiating therapy.
• Use caution in elderly patients due to heightened hypoglycemia risk.
• Avoid use in patients with known hypersensitivity to sulfonylureas.
• Do not prescribe during pregnancy or lactation unless benefits outweigh potential risks.
• Counsel patients to maintain regular meals and monitor blood glucose frequently.
• Review concomitant medications that may potentiate hypoglycemia.
• Adjust dose or discontinue if recurrent hypoglycemia occurs.

Glitisol can interact with several drugs that affect blood glucose levels or sulfonylurea metabolism.

Avoid

• Concurrent use with other insulin secretagogues (e.g., repaglinide, nateglinide) may cause additive hypoglycemia.
• Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) can increase glibenclamide plasma concentrations.
• Combining with high‑dose sulfonylureas or insulin may lead to severe hypoglycemia.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely.
• Thiazide diuretics can raise blood glucose; adjust antidiabetic regimen as needed.
• NSAIDs, especially ibuprofen, may impair renal function and affect drug clearance.